ICURE PHARM Revenue and Competitors
Estimated Revenue & Valuation
- ICURE PHARM's estimated annual revenue is currently $4.8M per year.
- ICURE PHARM's estimated revenue per employee is $201,000
Employee Data
- ICURE PHARM has 24 Employees.
- ICURE PHARM grew their employee count by 9% last year.
ICURE PHARM's People
Name | Title | Email/Phone |
---|
ICURE PHARM Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is ICURE PHARM?
Icure was established in year 2000 by a small team of dedicated scientists to provide R&D services to pharmaceutical firms interested in development and commercialization of novel transdermal drug delivery formulations. Since its inception, ICURE has endeavored to develop novel transdermal application products that are therapeutically effective, convenient to wear and promote high degree of patient compliance. In addition to its in-house R&D activities Icure engages in collaborative research projects with pharmaceutical firms and national research organizations involved in development of new drugs. Icure provides its input by developing by developing custom designed drug delivery systems to meet specific needs the drug compounds and their therapeutic targets.
keywords:N/AN/A
Total Funding
24
Number of Employees
$4.8M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.8M | 31 | -9% | N/A |
#2 | $7.2M | 55 | 6% | N/A |
#3 | $7.3M | 62 | -3% | N/A |
#4 | $18.1M | 72 | -6% | N/A |
#5 | $159.5M | 858 | 8% | $200M |